| Literature DB >> 18665162 |
G C Kabat1, A B Miller, M Jain, T E Rohan.
Abstract
Although folic acid has been investigated for its potential to inhibit carcinogenesis, few epidemiologic studies have assessed the effects of intake of thiamin, riboflavin, and niacin, which may reduce cancer risk by acting as cofactors in folate metabolism or by other mechanisms. Using data from a large cohort of Canadian women, we examined the association of dietary intake of these nutrients, as well as intake of folate, methionine, and alcohol, with cancers of the breast, endometrium, ovary, colorectum, and lung ascertained during an average of 16.4 years of follow-up. After exclusions, the following numbers of incident cases were available for analysis: breast, n=2491; endometrium, n=426; ovary, n=264; colorectum, n=617; and lung, n=358. Cox proportional hazard models were used to estimate risk of each cancer with individual nutrients and to explore possible effect modification by combinations of nutrients on cancer risk. Few significant associations of intake of individual B vitamins with the five cancers were observed. Alcohol consumption showed a modest positive association with breast cancer risk but not with risk of the other cancers. There was no evidence of effect modification among the nutrients. This large study provides little support for an association of dietary intake thiamin, riboflavin, niacin, folate, or methionine with five major cancers in women.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18665162 PMCID: PMC2528139 DOI: 10.1038/sj.bjc.6604540
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Pearson correlation coefficients for intake of B vitamins and other factors among 49 654 women in the NBSSa
|
|
|
|
|
| |
|---|---|---|---|---|---|
| Folate | |||||
| Thiamin | 0.49 | ||||
| Riboflavin | 0.43 | 0.32 | |||
| Niacin | 0.20 | 0.27 | 0.13 | ||
| Methionine | 0.12 | 0.18 | 0.47 | 0.56 | |
| Alcohol | −0.05 | −0.18 | −0.13 | −0.15 | −0.15 |
All correlations are significant at P<0.0001.
Multivariable-adjusted hazard ratios and 95% confidence intervals for the association of dietary intake of B-vitamins and other factors with risk of breast, endometrial, ovarian, colorectal, and lung cancer in the NBSS
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| <237 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 237 to <281 | 0.99 (0.87–1.13) | 0.91 (0.65–1.26) | 1.13 (0.78–1.64) | 0.99 (0.76–1.29) | 0.81 (0.59–1.11) |
| 281 to <321 | 1.03 (0.91–1.17) | 1.07 (0.78–1.48) | 0.91 (0.62–1.35) | 1.09 (0.84–1.41) | 0.64 (0.45–0.91) |
| 321 to <374 | 0.98 (0.86–1.12) | 1.12 (0.81–1.54) | 1.09 (0.74–1.59) | 1.12 (0.86–1.44) | 0.93 (0.67–1.28) |
| 374+ | 1.02 (0.90–1.17) | 0.79 (0.55–1.13) | 1.05 (0.71–1.54) | 0.89 (0.68–1.17) | 1.12 (0.83–1.52) |
|
|
|
|
|
|
|
| <1.06 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 1.06 to <1.19 | 1.08 (0.95–1.23) | 1.34 (0.96–1.86) | 0.91 (0.63–1.31) | 1.06 (0.82–1.36) | 0.96 (0.69–1.32) |
| 1.19 to <1.30 | 1.11 (0.98–1.27) | 1.19 (0.85–1.68) | 0.83 (0.57–1.21) | 1.12 (0.87–1.45) | 1.03 (0.75–1.42) |
| 1.30 to <1.43 | 1.05 (0.93–1.20) | 1.26 (0.90–1.77) | 0.88 (0.61–1.28) | 0.90 (0.69–1.17) | 1.13 (0.82–1.56) |
| 1.43+ | 1.04 (0.91–1.18) | 1.27 (0.90–1.78) | 0.78 (0.53–1.15) | 0.82 (0.62–1.08) | 0.99 (0.71–1.38) |
|
|
|
|
|
|
|
| <1.41 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 1.41 to <1.63 | 0.98 (0.86–1.11) | 0.86 (0.61–1.21) | 0.83 (0.57–1.20) | 1.03 (0.80–1.33) | 1.06 (0.76–1.46) |
| 1.63 to <1.86 | 0.96 (0.84–1.09) | 0.94 (0.68–1.32) | 0.90 (0.63–1.30) | 0.99 (0.77–1.28) | 1.08 (0.77–1.51) |
| 1.86 to <2.17 | 0.98 (0.87–1.12) | 0.79 (0.55–1.13) | 0.95 (0.66–1.36) | 0.85 (0.65–1.11) | 1.20 (0.86–1.67) |
| 2.17+ | 0.99 (0.87–1.12) | 0.78 (0.52–1.17) | 0.57 (0.37–0.86) | 0.94 (0.73–1.23) | 1.30 (0.94–1.80) |
|
|
|
|
|
|
|
| <16.9 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 16.9 to <18.7 | 0.96 (0.84–1.09) | 1.08 (0.79–1.47) | 1.09 (0.75–1.58) | 1.08 (0.84–1.39) | 1.14 (0.80–1.62) |
| 18.7 to <20.5 | 0.98 (0.86–1.11) | 1.05 (0.77–1.44) | 0.89 (0.60–1.32) | 1.08 (0.85–1.39) | 0.95 (0.66–1.35) |
| 20.5 to <22.8 | 0.97 (0.85–1.10) | 0.93 (0.67–1.28) | 1.05 (0.72–1.53) | 0.97 (0.75–1.25) | 1.03 (0.72–1.45) |
| 22.8+ | 0.97 (0.85–1.10) | 0.90 (0.64–1.26) | 0.98 (0.66–1.45) | 0.95 (0.74–1.23) | 1.19 (0.86–1.65) |
|
|
|
|
|
|
|
| <1.78 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 1.78 to <2.00 | 1.04 (0.92–1.19) | 0.90 (0.64–1.25) | 1.05 (0.73–1.51) | 0.99 (0.77–1.28) | 0.80 (0.58–1.10) |
| 2.00 to <2.20 | 1.08 (0.95–1.22) | 1.04 (0.76–1.43) | 0.80 (0.55–1.17) | 0.91 (0.71–1.18) | 0.73 (0.52–1.03) |
| 2.20 to <2.48 | 0.98 (0.86–1.12) | 0.93 (0.67–1.28) | 0.94 (0.64–1.37) | 0.92 (0.71–1.20) | 1.05 (0.77–1.42) |
| 2.48+ | 1.00 (0.88–1.14) | 0.77 (0.54–1.08) | 0.89 (0.61–1.31) | 0.99 (0.76–1.28) | 0.95 (0.69–1.31) |
|
|
|
|
|
|
|
|
| |||||
| Nondrinker | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| >0 to <5 g day−1 | 1.00 (0.90–1.12) | 1.15 (0.88–1.51) | 0.90 (0.63–1.29) | 0.92 (0.73–1.14) | 0.94 (0.69–1.27) |
| 5 to <10 g day−1 | 0.98 (0.86–1.13) | 1.00 (0.71–1.41) | 1.33 (0.89–1.96) | 0.93 (0.71–1.22) | 0.77 (0.52–1.13) |
| 10 to <20 g day−1 | 1.07 (0.93–1.23) | 1.21 (0.86–1.68) | 0.85 (0.54–1.32) | 1.04 (0.79–1.36) | 0.76 (0.53–1.11) |
| 20 to <30 g day−1 | 1.08 (0.89–1.32) | 1.34 (0.85–2.12) | 1.50 (0.88–2.56) | 1.13 (0.77–1.64) | 0.81 (0.49–1.34) |
| 30+ | 1.17 (0.98–1.39) | 0.84 (0.52–1.36) | 1.23 (0.74–2.04) | 1.02 (0.72–1.44) | 1.03 (0.71–1.51) |
|
|
|
|
|
|
|
Adjusted for age (continuous), body mass index (kg/m2 – continuous), pack-years of smoking (none, >0 to <10, 10 to <20, 20 to <30, 30+), years of education (three levels), menopausal status (pre-, peri-, post), family history of breast cancer (no, yes), history of breast biopsy (no, yes), age at menarche (<12, 12, 13, >13), parity (continuous), oral contraceptive use (never, ever), hormone replacement therapy (never, ever), and intake of calories (continuous). In addition, all nutrients except alcohol were adjusted for alcohol intake (continuous).
Adjusted for age (continuous), body mass index (kg/m2 – continuous), years of education (three levels), menopausal status (pre-, peri-, post), parity (continuous), age at menarche (<12, 12, 13, >13), oral contraceptive use (ever, never), hormone replacement therapy (never, ever), and intake of calories, calcium, and raw vegetables (all continuous). In addition, all nutrients except alcohol were adjusted for alcohol intake (continuous).
Adjusted for age (continuous), body mass index (kg/m2 – continuous), years of education (three levels), menopausal status (pre-, peri-, post), parity (continuous), duration of oral contraceptive use (4 levels), duration of hormone replacement use (4 levels), hysterectomy (yes/no).
Adjusted for age (continuous), body mass index (kg/m2 – continuous), pack-years of smoking (none, >0 to <10, 10 to <20, 20 to <30, 30+), years of education (3 levels), menopausal status (pre-, peri-, post), oral contraceptive use (never, ever), hormone replacement therapy (never, ever), and intake of calories (continuous). In addition, all nutrients except alcohol were adjusted for alcohol intake (continuous).
Adjusted for age (continuous), body mass index (kg/m2 – continuous), years of education (three levels), parous/nulliparous, smoking status, pack-years of smoking (Never, 1–9, 10–19, 20–29, 30–39, 40+), and alcohol (continuous).